[The leuko-stimulating and protective action of human recombinant interleukin-1 beta (betaleukin) in the chemotherapy of malignant tumors].

The investigation was concerned with the leuko-stimulating effect of interleukin-1 beta injected subcutaneously (4.6 +/- 0.3 ng/kg body), daily, for 10 days, to treat toxic leukopenia and neutropenia stage III in cancer patients.

[Betaleukin (human recombinant interleukin-1beta) for the prevention and correction of toxic leukopenia in chemotherapy of malignant neoplasms].

The marked and quick response to betaleukin, a preparation of recombinant human interleukin-1 beta, was demonstrated in 77 cases of extensive solid neoplasms and non-Hodgkin's disease, suffering combination chemotherapy-induced toxic leukopenia. Leukopoiesis was effectively stimulated by intravenous administration, of 10-20 ng/kg weight, dropwise for 5 days. Due to adjuvant betaleukin in identical dosage, chemotherapy was continued, in moderate leukopenia, without causing leukocyte count to drop.

[An interleukin-1 beta efficacy study in the treatment of combined radiation-thermal lesions].

The experiments were carried out on F1 (CBA x C57B16) male-mice. It was shown that, in contrast to a therapeutic effect of IL-1 for the solely irradiated mice, a single subcutaneous injection of 100 micrograms/kg recombinant human IL-1 beta in 4 h after a combined radiation-thermal injury (CRTI) increased significantly the death rate of the animals within the first 2-4 days. Administration of 150 ng IL-1 per mouse in 4, 24, or 48 h after the CRTI decreased an average life-span of mice.